George Davis (Photo courtesy of TEDCO) George Davis has been appointed CEO of TEDCO, the technology development corporation announced Wednesday morning.
TEDCO has announced its 2017 ICE award recipients, and two of the six winners have connections to Johns Hopkins. On May 25, AsclepiX CEO Wendy Perrow was named entrepreneur of the year, and Glyscend received an award for innovation.
Maryland Technology Development Corp. is offering $300,000 to the person or organization that comes up with the best idea for how to support and grow technology companies in the state.
TEDCO’s ICE awards returned to Columbus Center in Inner Harbor on Thursday night. The Maryland agency, which provides resources for startups and other businesses, awards portfolio companies for Innovation, Corporate Excellence and Entrepreneurship.
The Maryland Stem Cell Research Commission has awarded $8.5 million to 29 projects that will explore how human stem cells can regenerate heart tissue, treat muscular dystrophy and sickle cell disease, and aid diabetes management, among other medical conditions.
The Maryland Stem Cell Research Commission has approved awards of more than $8.5 million for companies and research institutes to address more than 20 diseases and conditions. The money will be spread among six companies and six research institutes in the state.
On Wednesday, March 22nd, the nonprofit Cybersecurity Association of Maryland, Inc. (CAMI), in partnership with PNC Bank and Point3 Security, hosted the inaugural Maryland Cybersecurity Awards Celebration.
Maryland startups made waves on a national stage this week, with all four finalists at the Association of University Technology Managers business plan competition coming from the state.
Over the course of four quarterly rounds over the next year, the new Minority Business Pre-Seed fund will award up to 10 African-American entrepreneurs with an investment up to $40,000 each to test business assumptions and build prototypes for initial market testing.
The investigational CardiAMP therapy is designed to deliver a high dose of a patient’s own bone marrow cells directly to the point of cardiac dysfunction, potentially stimulating the body’s natural healing mechanism after a heart attack.
